Lisa Scherber talks about what the first day of the Jimmy Fund Telethon has been like so far and the stories that have touched her the most.

Lisa Scherber talks about what the first day of the Jimmy Fund Telethon has been like so far and the stories that have touched her the most.

Hear stories of hope and inspiration for a cancer-free future from the annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance.

Hear stories of hope and inspiration for a cancer-free future from the annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance.

WEEI/NESN Jimmy Fund Radio-Telethon

Jimmy Fund Director Lisa Scherber recaps Day One so far

Arbella Insurance Vice President Gayle O'Connell brings a BIG donation check for the Jimmy Fund Radio Telethon.

Arbella Insurance Vice President Gayle O'Connell brings a BIG donation check for the Jimmy Fund Radio Telethon.

Gayle O'Connell and Arbella make a HUGE donation

Laurie H. Glimcher, MD, was named President and CEO of Dana-Farber Cancer
Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.

A trailblazer in cancer research, Dr. Glimcher's research identified key
transcriptional regulators of protective immunity and the origin of pathophysiologic
immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to medical literature.

Aside from her research efforts, Dr. Glimcher has been a staunch proponent of
improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed Dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute, Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.

Laurie H. Glimcher, MD, was named President and CEO of Dana-Farber Cancer Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.
A trailblazer in cancer research, Dr. Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to medical literature.
Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed Dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute, Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.

Laurie H. Glimcher, MD, Office of the President and CEO, Dana-Farber

In early 2020, it became difficult for Clinton to eat. It was during the pandemic
and much harder at the time to see a doctor, so it took a while before he was able to get checked out. In January 2021, Clinton was diagnosed with esophageal cancer that metastasized into his lungs.

His treatment included six months on a feeding tube, chemotherapy and radiation
treatments. In summer 2021, he received an esophagectomy and now comes in for
chemotherapy every other week. He will continue these sessions for the foreseeable
future.

The American Cancer Society estimates that there will be about 22,370 new
esophageal cancer cases diagnosed (17,690 in men and 4,680 in women) in 2024. Esophageal cancer is more common among men than among women. The
lifetime risk of esophageal cancer in the United States is about 1 in 127 in men and
about 1 in 434 in women.

In early 2020, it became difficult for Clinton to eat. It was during the pandemic and much harder at the time to see a doctor, so it took a while before he was able to get checked out. In January 2021, Clinton was diagnosed with esophageal cancer that metastasized into his lungs.
His treatment included six months on a feeding tube, chemotherapy and radiation treatments. In summer 2021, he received an esophagectomy and now comes in for chemotherapy every other week. He will continue these sessions for the foreseeable future.
The American Cancer Society estimates that there will be about 22,370 new esophageal cancer cases diagnosed (17,690 in men and 4,680 in women) in 2024. Esophageal cancer is more common among men than among women. The lifetime risk of esophageal cancer in the United States is about 1 in 127 in men and about 1 in 434 in women.

Jimmy Fund Director Lisa Scherber recaps Day One so far

In 1 playlist(s)

WEEI/NESN Jimmy Fund Radio-Telethon

Social links

Follow podcast

Recent clips